Palavras-chave
Monkeypox
Therapeutics
Treatment Efficacy
Orthopoxvirus
Como Citar
Resumo
Para esta revisión sistemática de la literatura, se realizó una descripción de las propuestas planteadas para el manejo farmacológico de la infección por viruela del mono (Mpox) durante el brote de 2022. Con ese objetivo, se realizó una revisión sistemática de la literatura utilizando palabras claves incluyendo: “Infections”, “Monkeypox”, “Therapeutics”, “Treatment Efficacy” en Medline a través de PubMed donde se identificaron 54 artículos publicados desde el año 2001 al año 2023, de los cuales 26 fueron seleccionados para ser incluidos en los resultados. Se encontró que el tratamiento más reportado para tratar la infección por Mpox fue el Tecovirimat, seguido del Cidofovir y el Brincidofovir. El Tecovirimat siendo la opción terapéutica más segura y eficaz, con la capacidad en reducir la carga viral del Mpox con una tasa de supervivencia de al menos un 90%. Sin embargo, ninguno de los tres medicamentos ha sido aprobado por la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA) para el tratamiento del Mpox por lo que se reconoce que es de fundamental importancia realizar estudios dirigidos para establecer esquemas de tratamiento a nivel mundial para el Mpox considerando que actualmente, el Mpox se considera como una potencial arma biológica a nivel mundial.
Ferrer R. Pandemia por COVID-19: el mayor reto de la historia del intensivismo. Med Intensiva. 2020 Aug;44(6):323-4. https://doi.org/10.1016/j.medin.2020.04.002
Khardori N. Vaccines and vaccine resistance: past, present and future. Indian J Med Microbiol. 2022 Apr;40(2):187-92. https://doi.org/10.1016/j.ijmmb.2021.12.008
Petersen E, Kantele A, Koopmans M, Asogun D, Yinka-Ogunleye A, Ihekweazu C, et al. Human Monkeypox: epidemiologic and clinical characteristics, diagnosis, and prevention. Infect Dis Clin North Am. 2019 Dec;33(4):1027-43. https://doi.org/10.1016/j.idc.2019.03.001
Thèves C, Biagini P, Crubézy E. The rediscovery of smallpox. Clin Microbiol Infect. 2014 Mar;20(3):210-8. https://doi.org/10.1111/1469-0691.12536
Rizk JG, Lippi G, Henry BM, Forthal DN, Rizk Y. Prevention and treatment of monkeypox. Drugs. 2022 Jun 28;82(9):957-63. https://doi.org/10.1007/s40265-022-01742-y
McCollum AM, Damon IK. Human Monkeypox. Clin Infect Dis. 2014 Jan 15;58(2):260-7. https://doi.org/10.1093/cid/cit703
Sudarmaji N, Kifli N, Hermansyah A, Yeoh SF, Goh BH, Ming LC. Prevention and treatment of monkeypox: a systematic review of preclinical studies. Viruses. 2022 Nov 11;14(11):2496. https://doi.org/10.3390/v14112496
Grosenbach DW, Honeychurch K, Rose EA, Chinsangaram J, Frimm A, Maiti B, et al. Oral tecovirimat for the treatment of smallpox. N Engl J Med. 2018 Jul 5;379(1):44-53. https://doi.org/10.1056/NEJMoa1705688
Russo AT, Grosenbach DW, Brasel TL, Baker RO, Cawthon AG, Reynolds E, et al. Effects of treatment delay on efficacy of tecovirimat following lethal aerosol monkeypox virus challenge in cynomolgus macaques. J Infect Dis. 2018 Sep 22;218(9):1490-9. https://doi.org/10.1093/infdis/jiy326
Smith SK, Self J, Weiss S, Carroll D, Braden Z, Regnery RL, et al. Effective antiviral treatment of systemic orthopoxvirus disease: st-246 treatment of prairie dogs infected with monkeypox virus. J Virol. 2011 Sep;85(17):9176-87. https://doi.org/10.1128/JVI.02173-10
Filippov E, Duhan S, Lehman L, Keisham B, Sethi V. Treatment failure in patient with severe Mpox and untreated HIV, Maryland, USA. Emerg Infect Dis. 2023 Jun;29(6). https://doi.org/10.3201/eid2906.230059
Shamim MA, Padhi BK, Satapathy P, Veeramachaneni SD, Chatterjee C, Tripathy S, et al. The use of antivirals in the treatment of human monkeypox outbreaks: a systematic review. Int J Infect Dis. 2023 Feb;127:150-61. https://doi.org/10.1016/j.ijid.2022.11.040
Lim EY, Whitehorn J, Rivett L. Monkeypox: a review of the 2022 outbreak. Br Med Bull. 2023 Apr 5;145(1):17-29. https://doi.org/10.1093/bmb/ldad002
Grosenbach DW, Berhanu A, King DS, Mosier S, Jones KF, Jordan RA, et al. Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice. Proc Nat Acad Sci. 2010 Jan 12;107(2):838-43. https://doi.org/10.1073/pnas.0912134107
Adler H, Gould S, Hine P, Snell LB, Wong W, Houlihan CF, et al. Clinical features and management of human monkeypox: a retrospective observational study in the UK. Lancet Infect Dis. 2022 Aug;22(8):1153-62. https://doi.org/10.1016/S1473-3099(22)00228-6
Beatty NL, Small C, Degener T, Henao Martinez AF. Monkeypox infection and resolution after treatment with tecovirimat in two patients with HIV disease. Ther Adv Infect Dis. 2022 Jan 21;9:204993612211383. https://doi.org/10.1177/20499361221138349
Warner BM, Klassen L, Sloan A, Deschambault Y, Soule G, Banadyga L, et al. In vitro and in vivo efficacy of tecovirimat against a recently emerged 2022 monkeypox virus isolate. Sci Transl Med. 2022 Nov 30;14(673). https://doi.org/10.1126/scitranslmed.ade7646
O’Laughlin K, Tobolowsky FA, Elmor R, Overton R, O’Connor SM, Damon IK, et al. Clinical use of tecovirimat (Tpoxx) for treatment of monkeypox under an investigational new drug protocol — United States, May-August 2022. MMWR Morb Mortal Wkly Rep. 2022 Sep 16;71(37):1190-5. https://doi.org/10.15585/mmwr.mm7137e1
McLean J, Stoeckle K, Huang S, Berardi J, Gray B, Glesby MJ, et al. Tecovirimat treatment of people with HIV During the 2022 Mpox outbreak. Ann Intern Med. 2023 May;176(5):642-8. https://doi.org/10.7326/M22-3132
Smith SK, Olson VA, Karem KL, Jordan R, Hruby DE, Damon IK. In vitro efficacy of ST246 against smallpox and monkeypox. Antimicrob Agents Chemother. 2009 Mar;53(3):1007-12. https://doi.org/10.1128/AAC.01044-08
Roper RL, Garzino-Demo A, Del Rio C, Bréchot C, Gallo R, Hall W, et al. Monkeypox (Mpox) requires continued surveillance, vaccines, therapeutics and mitigating strategies. Vaccine. 2023 May;41(20):3171-7. https://doi.org/10.1016/j.vacuna.2023.04.010
DeLaurentis CE, Kiser J, Zucker J. New perspectives on antimicrobial agents: tecovirimat for treatment of human monkeypox virus. Antimicrob Agents Chemother. 2022 Dec 20;66(12). https://doi.org/10.1128/aac.01226-22
De Clercq E. Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. Clin Microbiol Rev. 2001 Apr;14(2):382-97. https://doi.org/10.1128/CMR.14.2.382-397.2001
De Clercq E. Cidofovir in the treatment of poxvirus infections. Antiviral Res. 2002 Jul;55(1):1-13. https://doi.org/10.1016/s0166-3542(02)00008-6
Moschese D, Giacomelli A, Beltrami M, Pozza G, Mileto D, Reato S, et al. Hospitalisation for monkeypox in Milan, Italy. Travel Med Infect Dis. 2022 Sep;49:102417. https://doi.org/10.1016/j.tmaid.2022.102417
Stafford A, Rimmer S, Gilchrist M, Sun K, Davies EP, Waddington CS, et al. Use of cidofovir in a patient with severe mpox and uncontrolled HIV infection. Lancet Infect Dis. 2023 Jun;23(6):e218-26. https://doi.org/10.1016/S1473-3099(23)00044-0
Stittelaar KJ, Neyts J, Naesens L, van Amerongen G, van Lavieren RF, Holý A, et al. Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Nature. 2006 Feb 9;439(7077):745-8. https://doi.org/10.1038/naturaleza04295
Bloch EM, Sullivan DJ, Shoham S, Tobian AAR, Casadevall A, Gebo KA. The potential role of passive antibody-based therapies as treatments for monkeypox. mBio. 2022 Dec 20;13(6). https://doi.org/10.1128/mbio.02862-22
Kuroda N, Shimizu T, Hirano D, Ishikane M, Kataoka Y. Lack of clinical evidence of antiviral therapy for human monkeypox: a scoping review. J Infect Chemother. 2023 Feb;29(2):228-31. https://doi.org/10.1016/j.jiac.2022.10.009
Malik S, Ahmad T, Ahsan O, Muhammad K, Waheed Y. Recent developments in Mpox prevention and treatment options. Vaccines (Basel). 2023 Feb 21;11(3):500. https://doi.org/10.3390/vacunas11030500
Quenelle D, Collins D, Kern E. Cutaneous infections of mice with vaccinia or cowpox viruses and efficacy of cidofovir. Antiviral Res. 2004 Jul;63(1):33-40. https://doi.org/10.1016/j.antiviral.2004.02.003
Quenelle DC, Collins DJ, Kern ER. Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice. Antimicrob Agents Chemother. 2003 Oct;47(10):3275-80. https://doi.org/10.1128/AAC.47.10.3275-3280.2003
Mark Miller, Scott Barrett, DA Henderson. Chapter 62: Control and eradication. En: Jamison DT, Breman JG, Measham AR, Dean T Jamison, Joel G Breman, Anthony R Measham, et al., editores. Disease control priorities in developing countries. 2.ª ed. Washington (DC): World Bank Publications; 2006.
Martín-Delgado MC, Martín-Sánchez FJ, Martínez-Sellés M, Molero García JM, Moreno Guillén S, Rodríguez-Artalejo F, et al. Monkeypox in humans: a new outbreak. Rev Esp Quimioter. 2022 Jul 6. https://doi.org/10.37201/solicitud/059.2022
Bunge EM, Hoet B, Chen L, Lienert F, Weidenthaler H, Baer LR, et al. The changing epidemiology of human monkeypox—A potential threat? A systematic review. PLoS Negl Trop Dis. 2022 Feb 11;16(2):e0010141. https://doi.org/10.1371/journal.pntd.0010141
Mileto D, Riva A, Cutrera M, Moschese D, Mancon A, Meroni L, et al. New challenges in human monkeypox outside Africa: a review and case report from Italy. Travel Med Infect Dis. 2022 Sep;49:102386. https://doi.org/10.1016/j.tmaid.2022.102386
De Sousa D, Patrocínio J, Frade J, Correia C, Borges-Costa J, Filipe P. Human monkeypox coinfection with acute HIV: an exuberant presentation. Int J STD AIDS. 2022 Sep 13;33(10):936-8. https://doi.org/10.1177/09564624221114998
Gonzalo-Salado M, García-Sánchez S, Silva-Cuevas M, García-Luque A. Evaluación positiva de medicamentos: septiembre, octubre, noviembre y diciembre de 2021. Sanidad Militar. 2022 Sep 19;78(1):33-41. https://doi.org/10.4321/s1887-85712022000100007.
Organización Panamericana de la Salud. Opciones terapéuticas para la viruela símica: síntesis de evidencia. Revisión rápida. Washington; 2022.
Siegrist EA, Sassine J. Antivirals with activity against mpox: a clinically oriented review. Clin Infect Dis. 2023 Jan 6;76(1):155-64. https://doi.org/10.1093/cid/ciac622
Russo AT, Grosenbach DW, Chinsangaram J, Honeychurch KM, Long PG, Lovejoy C, et al. An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications. Expert Rev Anti Infect Ther. 2021 Mar 4;19(3):331-44. https://doi.org/10.1080/14787210.2020.1819791
Shamim MA, Padhi BK, Satapathy P, Veeramachaneni SD, Chatterjee C, Tripathy S, et al. The use of antivirals in the treatment of human monkeypox outbreaks: a systematic review. Int J Infect Dis. 2023 Feb;127:150-61. https://doi.org/10.1016/j.ijid.2022.11.040
Almehmadi M, Allahyani M, Alsaiari AA, Alshammari MK, Alharbi AS, Hussain KH, et al. A glance at the development and patent literature of tecovirimat: the first-in-class therapy for emerging monkeypox outbreak. Viruses. 2022 Aug 25;14(9):1870. https://doi.org/10.3390/v14091870
Kumar AM, Chen ST, Merola JF, Mostaghimi A, Zhou XA, Fett N, et al. Monkeypox outbreak, vaccination, and treatment implications for the dermatologic patient: review and interim guidance from the Medical Dermatology Society. J Am Acad Dermatol. 2023 Mar;88(3):623-31. https://doi.org/10.1016/j.jaad.2022.10.050
Huston J, Curtis S, Egelund EF. Brincidofovir: a novel agent for the treatment of smallpox. Ann Pharmacother. 2023 Jan 23;106002802311517. https://doi.org/10.1177/10600280231151751
Siegrist EA, Sassine J. Antivirals with activity against mpox: a clinically oriented review. Clin Infect Dis. 2023 Jan 6;76(1):155-64. https://doi.org/10.1093/cid/ciac622
Mateos Moreno D, Clavo Escribano P. Infección por virus de la viruela del mono: caso clínico. Actas Dermosifilogramas. 2023 Jan;114(1):83-5. https://doi.org/10.1016/j.ad.2022.06.014
Kukreja S, Ochani S, Kalwar A, Lohana S, Ullah K. Re-administration of SmallPox vaccine against MonkeyPox among general population; after more than 30 Years of vaccine cessation by WHO. Ann Med Surg. 2022 Sep;81. https://doi.org/10.1016/j.amsu.2022.104519
Mungmunpuntipantip R, Wiwanitkit V. Smallpox vaccination discontinuation and monkeypox incidence in an African endemic region: a reanalysis on the relationship between the withdrawal of smallpox vaccine and subsequent morbidity. Am J Clin Exp Immunol. 2022;11(5):78-83.
Kumar P, Chaudhary B, Yadav N, Devi S, Pareek A, Alla S, et al. Recent advances in research and management of human monkeypox virus: an emerging global health threat. Viruses. 2023 Apr 10;15(4):937. https://doi.org/10.3390/v15040937
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Natalia Coriat-Cruz, Freddy Moreno-Gómez, Sofía Cepeda-Londoño